Aranesp and Developmental delay - a phase IV clinical study of FDA data

Summary:

Developmental delay is reported as a side effect among people who take Aranesp (darbepoetin alfa), especially for people who are male, 0-1 old, have been taking the drug for < 1 month also take Cellcept, and have Chronic renal failure.

The phase IV clinical study analyzes which people have Developmental delay when taking Aranesp. It is created by eHealthMe based on reports of 54,218 people who have side effects when taking Aranesp from the FDA, and is updated regularly.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

What is Developmental delay?

Developmental delay is found to be associated with 359 drugs and 428 conditions by eHealthMe. Check the latest studies of Developmental delay.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

54,218 people reported to have side effects when taking Aranesp.
Among them, 12 people (0.02%) have Developmental delay.

Could Aranesp cause Developmental delay?

Among these 12 people:

How long have people been on Aranesp when they have Developmental delay? *

What is the gender of people who have Developmental delay when taking Aranesp? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Developmental delay when taking Aranesp? *

What are other drugs people take besides Aranesp? *

What are other side effects people have besides Developmental delay? *

Wheezing (a high-pitched whistling sound made while you breath): 10 people, 83.33%
Aplasia Pure Red Cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells): 10 people, 83.33%
Enterococcal Infection: 10 people, 83.33%
Staphylococcal Infection (an infection with staphylococcus bacteria): 10 people, 83.33%
Respiratory Distress (difficulty in breathing): 10 people, 83.33%
Transplant Rejection (a transplant material is not worked): 8 people, 66.67%
Fever: 8 people, 66.67%
Device Related Infection: 8 people, 66.67%
Thrombosis (formation of a blood clot inside a blood vessel): 7 people, 58.33%
Staphylococcus Test Positive: 7 people, 58.33%

What are the existing conditions these people have? *

Chronic Renal Failure (kidney failure): 5 people, 41.67%
Chronic Kidney Disease: 2 people, 16.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 8.33%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 8.33%
Polyarthritis (arthritis which involves 5 or more joints simultaneously): 1 person, 8.33%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Aranesp and have Developmental delay?

- Check whether Developmental delay is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aranesp:

Aranesp (54,331 reports)

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Developmental delay:

Developmental delay (359 drugs)

Browse all the conditions that are associated with Developmental delay:

Developmental delay (428 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on darbepoetin alfa (the active ingredients of Aranesp) and Aranesp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.